Ruediger S. Goertz

Measurement of Liver Elasticity with Acoustic Radiation Force Impulse (ARFI) Technology: An Alternative Noninvasive Method for Staging Liver Fibrosis in Viral Hepatitis

PURPOSE The acoustic radiation force impulse (ARFI) technology is a novel ultrasound method that provides information about the local elasticity of tissue in real-time. ARFI is integrated in a conventional ultrasound system. The aim of this exploratory study was to evaluate this new technique in the assessment of liver fibrosis in a cohort with chronic viral hepatitis B and C and to ascertain the most reliable hepatic segment for measurements. MATERIALS AND METHODS 57 patients (27 female, 30 male, mean age 54 years) with chronic viral hepatitis B and C underwent ARFI imaging and consecutively liver biopsy. The results were compared to the histological fibrosis degree (F), which served as the reference. 20 healthy volunteers received ARFI quantification of different segments of the liver. RESULTS The best ARFI assessments with the lowest rate of invalid measurements were carried out by an intercostal approach to segment VII/VIII of the liver. The ARFI velocities of the healthy group had a mean of 1.09 m/s (range 0.79 - 1.32 m/s), the means of the patient group ranged from 0.83 to 4.19 m/s. ARFI quantification correlated significantly with the histological fibrosis stage (p < 0.001). The area under the receiver operating characteristic (ROC) curves for the accuracy of ARFI imaging was 85 %, 92 % and 87 % for the diagnosis of moderate fibrosis (>or= F2), severe fibrosis (>or= F3) and cirrhosis ( = F 4), respectively. CONCLUSION This study underscores the usefulness of ARFI as a quick method for assessing liver fibrosis or cirrhosis in patients with HBV or HCV. ARFI measurements of the liver should be performed via an intercostal access. Increasing ARFI velocities correlate with higher degree of hepatic fibrosis.

An abdominal and thyroid status with Acoustic Radiation Force Impulse Elastometry -A feasibility study Acoustic Radiation Force Impulse Elastometry of human organs

PURPOSE Acoustic Radiation Force Impulse (ARFI) is a new method for the quantification of tissue elasticity. To date, ARFI technology has not been applied systematically to establish an abdominal and thyroid status. The aim of this prospective feasibility study was to evaluate ARFI elastometry performed on various healthy abdominal organs and the thyroid gland. MATERIAL AND METHODS 94 patients (43 females, 51 males) with a mean age of 54 years and 20 healthy controls were enrolled in the study. A routine ultrasound examination of the abdomen was scheduled in 72, and of the thyroid in 25. ARFI elastometry was performed in liver, spleen, pancreas, prostate, kidneys and thyroid gland with the ultrasound system Acuson S2000. ARFI values are proportional to tissue elasticity. Patients with ultrasonic or anamnestic evidence of diseased organs were excluded from the analysis. ARFI measurements were compared with the aid of the t-test and correlated using Spearmans correlation coefficient. RESULTS ARFI elastometry proved feasible and the measurements obtained in the various organs differed significantly. Among healthy organs the spleen showed the highest mean ARFI velocities, followed by the kidney, thyroid, pancreas and the prostate. The lowest ARFI values were regularly found in healthy liver. Measurements in the kidneys and the spleen showed high standard deviation. CONCLUSIONS ARFI elastometry may describe parenchymal stiffness of various abdominal organs and the thyroid gland. Further investigations are needed to compare these baseline findings in healthy organs with those of various tumours or diseases affecting the individual organs.

Diagnostics in inflammatory bowel disease: ultrasound.

Diagnosis of chronic inflammatory bowel diseases (IBD) is based on a combination of clinical symptoms, laboratory tests and imaging data. Imaging of the morphological characteristics of IBD includes the assessment of mucosal alterations, transmural involvement and extraintestinal manifestations. No single imaging technique serves as a diagnostic gold standard to encompass all disease manifestations. Ultrasound, computed tomography (CT) or magnetic resonance imaging (MRI) allow cross-sectional imaging of the transmural alterations and extraintestinal manifestations. While in the USA the technique of choice is CT, in Europe the focus is more on MRI and ultrasound (US). Most patients with chronic IBD are diagnosed at a young age. After baseline diagnosis many of these young patients have to undergo repetitive imaging procedures during the variable clinical course of the disease, characterized by alternate periods of remission and active disease, and in monitoring the response to treatment. US has the advantage of being noninvasive, less costly, and easily repeatable, and thus can be very useful in following up patients with IBD. In addition, rising concern about radiation exposure in young adults indicates the demand for radiation-sparing techniques like US and MRI. This article focuses on the current clinical practice of US in IBD, describing the current technologies used in transabdominal intestinal US and the characteristic sonographic findings in Crohn´s disease and ulcerative colitis.

EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography, Update 2017 (Long Version)

We present here the first update of the 2013 EFSUMB (European Federation of Societies for Ultrasound in Medicine and Biology) Guidelines and Recommendations on the clinical use of elastography with a focus on the assessment of diffuse liver disease. The short version provides clinical information about the practical use of elastography equipment and interpretation of results in the assessment of diffuse liver disease and analyzes the main findings based on published studies, stressing the evidence from meta-analyses. The role of elastography in different etiologies of liver disease and in several clinical scenarios is also discussed. All of the recommendations are judged with regard to their evidence-based strength according to the Oxford Centre for Evidence-Based Medicine Levels of Evidence. This updated document is intended to act as a reference and to provide a practical guide for both beginners and advanced clinical users.

Characterization of Focal Liver Lesions (FLL) with Acoustic Radiation Force Impulse (ARFI) Elastometry

PURPOSE The technology of acoustic radiation force impulse (ARFI) represents an innovative method for the quantification of tissue elasticity. The aim of this prospective pilot study was to evaluate the role of ARFI elastometry of focal liver lesions (FLL) and the surrounding liver parenchyma. MATERIALS AND METHODS All patients with unclear FLL in B-mode ultrasound were assigned to ARFI elastometry (m/sec). Measurement sites were located within the FLL, in the peritumoral tissue and in hepatic segment VIII (intercostal approach). Histology and CEUS served as the reference for the characterization of the lesions. RESULTS A total of 81 patients were enrolled, of whom 62 patients (39 females, 23 males; mean age 54 years) had FLL measurable by means of ARFI. The lesions were: 38 benign (61 %) and 24 malignant FLL (39 %). The ARFI elastometric values of the FLL differed significantly from those of the liver parenchyma (p < 0.001). Elastometry of benign lesions and of malignant tumors showed statistically comparable results (p = 0.28). The lowest ARFI values were observed in focal fatty sparing and the highest in CCC. Only focal fatty sparing and HCC showed negative differences between FLL and peritumoral tissue or liver parenchyma. In 23 % of the hepatic lesions, no reliable quantitative ARFI results were obtainable due to false, inconsistent or technically failed measurements. CONCLUSION FLL vary in ARFI elastometry. However, high ARFI values occur in benign as well as in malignant lesions and do not permit differentiation between them.

Dynamic contrast-enhanced ultrasound (DCE-US) for the characterization of hepatocellular carcinoma and cholangiocellular carcinoma.

PURPOSE In a prospective study, we compared the different perfusion kinetics of HCC and ICC using dynamic contrast-enhanced ultrasound (DCE-US). MATERIALS AND METHODS Patients with proven HCC and ICC were included. Three-minute video clips of CEUS examinations (CPS - low MI mode) after a bolus injection of 1.2 ml SonoVue were recorded and analyzed with quantification software (VueBox). Parameters for the arterial contrast enhancement [rise time (RT), time-to-peak (TTP)] towards portal venous contrast enhancement [mean transit time (local) (mTTl) and fall time (FT)] were quantified. Furthermore, contrast wash-out after peak enhancement (PE) (40 s, 80 s, 100 s and 120 s after PE) was compared between HCC and ICC. RESULTS 43 patients with proven HCC (n = 23 HCC; cirrhosis n = 16) and ICC (n = 20 ICC; Cirrhosis n = 6) were examined. No statistical difference of the arterial DCEUS parameters was found between HCC and ICC. Contrast enhancement of the portal venous and late phases showed significantly lower values in the ICC group indicating early wash-out of the contrast agent: mTTl (p = 0.0209): HCC 118.4 s (SD± 88.4); ICC 64.8 s (SD± 49.7). FT (p = 0.0433): HCC 42.5 s (SD± 27.7); ICC 27.7 s (SD± 16.2). The percental loss of intensity at a definite time point after PE was significantly higher in ICC than in HCC lesions. CONCLUSION DCE-US is able to detect and quantify differences in perfusion kinetics between HCC and ICC. Whereas arterial contrast enhancement patterns may overlap between HCC and ICC, a timed characterization of wash-out kinetics may offer an additional tool to characterize HCC and ICC. The presence of a rapid loss of signal intensity in the early portal venous phase is significantly higher in ICC than in HCC lesions.

Software-based quantification of contrast-enhanced ultrasound in focal liver lesions—A feasibility study

PURPOSE To compare software-based quantification of contrast-enhanced ultrasound (CEUS) examinations of focal liver lesions in the arterial and late phases with the enhancement patterns established by the sonologist. MATERIALS AND METHODS The study cohort comprised 12 malignant and 21 benign hepatic lesions in 33 patients (18 female and 15 male; aged 57 +/- 13 years). All underwent dynamic real-time low mechanical index (<0.3) CEUS, which was stored as video sequences of the various enhancement phases. A software was used for analysis by using different regions of interest (ROI) in a double-blinded manner. The software generated and the visual enhancement patterns were compared, and the t-test was performed. RESULTS The videos containing the arterial phase had a mean length of 37.5 +/- 36.7 s and the late phase sequences a mean length of 15.2 +/- 9.2 s. In the arterial phase complete agreement between software and sonologist was 100%, 93.9% and 87.9% with regard to the entire lesion, its centre and its periphery, respectively. The late phase analysis revealed corresponding figures of 90.9%, 87.9% and 90.9%. In the late phase, benign lesions revealed a mean relative enhancement of +65.1 +/- 103.6% and malignant lesions -56.9 +/- 26.3% (p=0.0005) vis-à-vis liver parenchyma. All the malignant and 14% of the benign tumors showed hypo-enhancement of less than -10%. CONCLUSION The complete agreement between the quantitative analysis and the sonologist within the arterial and late phase showed excellent results. Software analysis of the late phase could dichotomise benign and malignant lesions. Objective establishment of iso-enhancement in the late phase excludes malignancy.

Early response to anti-tumoral treatment in hepatocellular carcinoma--can quantitative contrast-enhanced ultrasound predict outcome?

PURPOSE In order to detect an early response to anti-angiogenic therapy, this study aims at analyzing specific effects of a sorafenib-based regime on intra-tumoral D-CEUS flow parameters of patients with HCC. MATERIALS AND METHODS Videos of the arterial phase were captured before initiation of a therapy with sorafenib and 1 and 3 months after (n = 9). Patients receiving a non-anti-angiogenic therapy (TACE, n = 10) served as a comparison group. Cross-sectional imaging was performed at the same time points and patients were followed up for 1 year. RESULTS In the responder group (RE), the absolute (percentage) TTP was 11.28 s ± 2.03 s (1.00) before treatment, 13.60 s ± 1.52 s (1.53 ± 0.08) after one month (p = 0.0405), and 16.17 s ± 2.35 s (1.46 ± 0.07) after three months of treatment (p = 0.0071). The TTP increased significantly in the RE group as early as 1 month after initiation of sorafenib compared to the non-responder group. There were no significant differences in the non-responder group or between the NR and the TACE group at any time point. D-CEUS values from all sorafenib-treated patients showed good accordance with RECICL (response evaluation criteria in cancer of the liver) criteria (R2 = 0.7154, p = 0.0001). CONCLUSIONS Quantitative CEUS reveals variations of dynamic parameters of blood flow during anti-tumoral therapy in liver cancer patients. Further investigations and clinical trails have to confirm that the TTP is a promising parameter in the prediction of early response to sorafenib-based therapy.

Impact of Biopsy on the Accuracy of Endorectal Ultrasound Staging of Rectal Tumors

PurposeEndorectal ultrasound is a well-established method for the preoperative staging of rectal tumors. This prospective study was performed to establish whether obtaining a biopsy before endorectal ultrasound has an influence on staging accuracy.MethodsBetween 1990 and 2003, a total of 333 rectal tumors were examined preoperatively by using endorectal ultrasound. All patients underwent rectal resection, and the specimens were sent for histologic evaluation. Thirty-three were not biopsied, the remaining at various times before endorectal ultrasound. The chi-squared test or Fisher’s exact test were used for statistical analysis to compare the accuracies.ResultsThe overall staging accuracy was 71 percent but differed significantly (P = 0.004) between the groups as a function of time elapsed since biopsy. The best results were seen in tumors that were not biopsied before endorectal ultrasound, which were correctly staged in 85 percent of the cases. The least accurate staging (53 percent) was noted when endorectal ultrasound was performed in the third week after biopsy, mostly as a result of overstaging. Biopsy did not have a significant effect on nodal staging.ConclusionsBiopsy before endorectal ultrasound significantly affects its accuracy. To achieve the most accurate staging, biopsy should be performed after endorectal ultrasound. Endorectal ultrasound staging performed in the first week after biopsy is the second best option but should be interpreted with caution in the second or third week.

Multispectral Optoacoustic Tomography in Crohn’s Disease: Noninvasive Imaging of Disease Activity

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.